Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
#:"(allfields_unstemmed:2019-nCov OR allfields:2019nCov OR allfields_unstemmed:2019nCov OR allfields_unstemmed:Sars-CoV-2 OR allfields_unstemmed:COVID-19 OR allfields_unstemmed:Sars-CoV-2 OR allfields_unstemmed:COVID-19 NOT format:Book NOT collection_details:ZDB-2-SEB)"
(allfields_unstemmed:2019-nCov OR allfields:2019nCov OR allfields_unstemmed:2019nCov OR allfields_unstemmed:Sars-CoV-2 OR allfields_unstemmed:COVID-19 OR allfields_unstemmed:Sars-CoV-2 OR allfields_unstemmed:COVID-19 NOT format:Book NOT collection_details:ZDB-2-SEB)
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=%23%3A%22%28allfields_unstemmed%3A2019-nCov+OR+allfields%3A2019nCov+OR+allfields_unstemmed%3A2019nCov+OR+allfields_unstemmed%3ASars-CoV-2+OR+allfields_unstemmed%3ACOVID-19+OR+allfields_unstemmed%3ASars-CoV-2+OR+allfields_unstemmed%3ACOVID-19++NOT+format%3ABook+NOT+collection_details%3AZDB-2-SEB%29%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject&page=2
/vufind/Search/Results?filter%5B%5D=%23%3A%22%28allfields_unstemmed%3A2019-nCov+OR+allfields%3A2019nCov+OR+allfields_unstemmed%3A2019nCov+OR+allfields_unstemmed%3ASars-CoV-2+OR+allfields_unstemmed%3ACOVID-19+OR+allfields_unstemmed%3ASars-CoV-2+OR+allfields_unstemmed%3ACOVID-19++NOT+format%3ABook+NOT+collection_details%3AZDB-2-SEB%29%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject&page=2
Search /vufind/Search2/Results?filter%5B%5D=%23%3A%22%28allfields_unstemmed%3A2019-nCov+OR+allfields%3A2019nCov+OR+allfields_unstemmed%3A2019nCov+OR+allfields_unstemmed%3ASars-CoV-2+OR+allfields_unstemmed%3ACOVID-19+OR+allfields_unstemmed%3ASars-CoV-2+OR+allfields_unstemmed%3ACOVID-19++NOT+format%3ABook+NOT+collection_details%3AZDB-2-SEB%29%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject&page=2
PubPharm (1.074)
11
A Study to Learn About a Repeat 5-Day Treatment with Nirmatrelvir/Ritonavir in People with Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment with Nirmatrelvir/Ritonavir : AN INTERVENTIONAL, EFFICACY AND SAFETY, PHASE 2, RANDOMIZED, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE A REPEAT 5-DAY COURSE OF NIRMATRELVIR/RITONAVIR COMPARED TO PLACEBO/RITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID-19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
12
A Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab in Pediatric Patients Hospitalized with COVID-19 : A PHASE Ib, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF TOCILIZUMAB IN PEDIATRIC PATIENTS HOSPITALIZED WITH COVID-19 - N/A
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
13
A Multicentre, Open label, Randomised, Controlled, Basket, Pragmatic, Phase II, Clinical and Translational Study to Determine the Efficacy and Safety of Plitidepsin versus Control in Immunocompromised Adult Patients with Symptomatic COVID-19 requiring Hospital Care (NEREIDA) : A Multicentre, Open label, Randomised, Controlled, Basket, Pragmatic, Phase II, Clinical and Translational Study to Determine the Efficacy and Safety of Plitidepsin versus Control in Immunocompromised Adult Patients with Symptomatic COVID-19 requiring Hospital Care (NEREIDA)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
14
Evaluation of the efficacy and safety of a polyclonal equine fragments immunotherapy (FBR-002) in participants with COVID-19 requiring supplemental oxygen in hospital and at risk of severe outcome : A phase IIb randomized, placebo-controlled, double-blind study, to evaluate the efficacy and safety of FBR-002 in participants hospitalized with COVID-19 in need of supplemental oxygen and at risk of severe outcome
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
15
A Phase 3 blinded study to assess the efficacy and safety of Favipiravir vs placebo in Non-critical Hospitalized Patients with COVID-19 Pneumonia (PROVIR) : A Phase 3, Multicenter, Prospective, Placebo-Controlled, Randomized, Double-Blind Study to Assess the Efficacy and Safety of Favipiravir in Non-critical Hospitalized Patients with COVID-19 Pneumonia (PROVIR) - PROVIR
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
16
Safety and immunogenicity of RNA-based vaccines against SARS-CoV-2 variants in healthy participants : A Phase II trial to evaluate the safety and immunogenicity of SARS-CoV-2 monovalent and multivalent RNA-based vaccines in healthy subjects
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
17
A Study to Learn About the Study Medicines Called Nirmatrelvir/Ritonavir in People at Least 12 Years of Age With COVID-19 Who Are Immunocompromised : AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2, RANDOMIZED, DOUBLE-BLIND, 3-ARM STUDY TO INVESTIGATE NIRMATRELVIR/RITONAVIR IN NONHOSPITALIZED PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH SYMPTOMATIC COVID-19 WHO ARE IMMUNOCOMPROMISED
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
18
A phase I/III study to assess pre-exposure prophylaxis of AZD5156 in immunocompromised individuals : A Phase I/III Randomized, Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156 for Pre-exposure Prophylaxis of COVID-19 in Participants with Conditions Causing Immune Impairment - SUPERNOVA
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
19
A Study to Learn About the Study Medicines Called Nirmatrelvir/Ritonavir in People at Least 12 Years of Age With COVID-19 Who Are Immunocompromised : AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2, RANDOMIZED, DOUBLE-BLIND, 3-ARM STUDY TO INVESTIGATE NIRMATRELVIR/RITONAVIR IN NONHOSPITALIZED PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH SYMPTOMATIC COVID-19 WHO ARE IMMUNOCOMPROMISED
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
20
A phase II study to evaluate safety and immunogenicity of recombinant proteincandidate vaccine against SARS-CoV-2 in adults fully vaccinated against COVID-19 with extension period to evaluate a fourth dose : A Phase IIb, double-blind, randomized, active controlled, multi-centre, non-inferiority trial followed by a Phase III, single arm, open label trial, to assess immunogenicity and safety of a booster vaccination with a recombinant protein RBD fusion dimer candidate (PHH-1V) against SARS-CoV-2, in adults fully vaccinated against COVID-19 followed with an extension period to study a fourth dose administration of PHH-1V.
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
[1]
« Vorheriger
1
2
3
4
5
6
7
8
9
10
11
Nächster »
[108]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Filter aufheben
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Medienart
1.074
Aufsätze
1.074
E-Artikel
1.074
E-Ressourcen
Zeitschriftentitel
1.074
WHO International Clinical Trials Registry Plat...
Thema
1.074
610
1.074
Recruitment Status: Authorised-recruitment may ...
1.074
Study Type: Interventional
484
Phase: Phase 2
314
Phase: Phase 3
220
Phase: Phase 4
56
Phase: Phase 1
38
Medical Condition: COVID-19;Therapeutic area: D...
14
Medical Condition: Acute respiratory distress s...
14
Medical Condition: Protection against COVID-19 ...
12
Medical Condition: COVID-19 MedDRA version: 23....
12
Medical Condition: COVID-19 MedDRA version: 23....
12
Medical Condition: COVID-19 MedDRA version: 23....
12
Medical Condition: COVID-19 infection MedDRA ve...
12
Medical Condition: Coronavirus Disease 2019 (CO...
10
Medical Condition: COVID-19 MedDRA version: 23....
10
Medical Condition: COVID-19;Therapeutic area: D...
10
Medical Condition: Healthy Volunteers, with or ...
10
Medical Condition: Moderate to severe coronavir...
10
Medical Condition: moderate COVID-19 infection ...
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
32
2023
236
2022
426
2021
380
2020
Erscheinungsjahr(e)
Von:
Bis:
Sprache
1.042
Englisch
26
Unbestimmt
2
Französisch
2
Deutsch
2
Polnisch
Alle anzeigen ...
weniger ...
Haven't found what you're looking for?
Wird geladen...